For gene therapy, now-quantified risks are deemed troubling.
作者信息
Twombly Renee
出版信息
J Natl Cancer Inst. 2003 Jul 16;95(14):1032-3. doi: 10.1093/jnci/95.14.1032.
PMID:12865444
Abstract
摘要
相似文献
1
For gene therapy, now-quantified risks are deemed troubling.
J Natl Cancer Inst. 2003 Jul 16;95(14):1032-3. doi: 10.1093/jnci/95.14.1032.
2
Success for gene therapy: render unto Caesar that which is Caesar's.
Genome Biol. 2004;5(8):237. doi: 10.1186/gb-2004-5-8-237. Epub 2004 Jul 29.
3
Gene therapists hopeful as trials resume with childhood disease.
Nature. 2004 Jun 10;429(6992):587. doi: 10.1038/429587a.
4
[Development and application of gene therapy technologies].
Uirusu. 2004 Jun;54(1):49-57. doi: 10.2222/jsv.54.49.
5
Risks and benefits of gene therapy.
N Engl J Med. 2003 Jan 16;348(3):193-4. doi: 10.1056/NEJMp020184.
6
Gene therapy for SCID--a complication after remarkable progress.
Lancet. 2002 Oct 19;360(9341):1185-6. doi: 10.1016/S0140-6736(02)11290-6.
7
Stem cell clonality and genotoxicity in hematopoietic cells: gene activation side effects should be avoidable.
Semin Hematol. 2004 Oct;41(4):303-18. doi: 10.1053/j.seminhematol.2004.07.007.
8
Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1.
J Clin Invest. 2008 Sep;118(9):3132-42. doi: 10.1172/JCI35700.
9
Genetic modification of somatic stem cells. The progress, problems and prospects of a new therapeutic technology.
EMBO Rep. 2008 Jul;9 Suppl 1(Suppl 1):S64-9. doi: 10.1038/embor.2008.81.
10
Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients.
J Clin Invest. 2008 Sep;118(9):3143-50. doi: 10.1172/JCI35798.
Zotero 插件